Quick answer
Tirzepatide is verified by HPLC (purity) and mass spectrometry (identity, about 4,813 Da); its lipid side chain makes mass confirmation and acylation-related impurities especially important.
- Formula: C225H348N48O68; 39 residues with two Aib residues and a C20 fatty diacid linked through a spacer
- Listed purity: ≥98% by HPLC on the product page
- Distinct impurities: des-acyl, over-acylated, oxidized and deamidated forms
- Document: a lot-specific COA with chromatogram, observed mass, method and date (see the CoA page)
- Not covered: sterility, endotoxin and activity need separate evidence
- Research use: For laboratory research use only; not for human consumption.
For laboratory research use only; not for human consumption.
A vial with the correct label is not the same thing as a vial with verified contents, and for a fatty-acid-conjugated peptide like tirzepatide that distinction is especially important. This guide explains what each analytical technique establishes for tirzepatide, which impurities are specific to its structure, how to read a lot-specific certificate, and what testing leaves unanswered. The material discussed is the tirzepatide research peptide, a 30 mg lyophilized vial listed at ≥98% purity by HPLC.
What makes tirzepatide analytically distinctive
Tirzepatide is a 39-residue linear peptide built on the GIP sequence, with a C-terminal amide, two non-proteinogenic α-aminoisobutyric acid (Aib) residues, and a C20 fatty diacid attached through a short hydrophilic linker to a lysine side chain. Its formula is C225H348N48O68, which corresponds to an average mass of about 4,813 Da. The Aib residues and the lipid side chain are the features that set its quality profile apart from an unmodified peptide of similar length. Background on the molecule and its brand-chemistry context is in tirzepatide research overview and is tirzepatide a peptide?
| Structural feature | Why it matters for testing |
|---|---|
| 39 residues, linear, C-terminal amide | Long chain: more opportunity for deletion and truncation products during synthesis |
| Two Aib residues | Non-standard residues; a wrong substitution changes mass by a small, specific amount |
| C20 fatty diacid through a linker | Greatly increases hydrophobicity; retention in reversed-phase HPLC is later than the unmodified backbone |
| Single acylation site | Incomplete or misplaced acylation gives a mass shift or a closely eluting isomer |
| Contains Trp and several Gln/Asp/Ser | Oxidation (+16 Da) and deamidation (+1 Da) are plausible degradation routes |
| Average mass about 4,813 Da | Appears as several multiply charged ions that are deconvoluted to the neutral mass |
What purity testing verifies
Two separate questions need separate answers: how pure is the material, and is it actually the molecule it claims to be? High-performance liquid chromatography answers the first question by separating a sample into its components and reporting the percentage of total peak area attributable to the target compound, commonly reported as a value such as ≥98% for research-grade tirzepatide. Mass spectrometry answers the second question, measuring the molecular mass of the isolated peak and comparing it against the expected mass for tirzepatide’s formula, C225H348N48O68.
A peptide carrying a fatty-diacid side chain conjugated through a linker is more structurally complex than an unmodified peptide chain, which makes mass confirmation particularly informative. An error in the acylation step during synthesis, for instance, would show up as a mass shift even if the chromatography trace looked clean. The distinction between these two techniques, and why both matter together, is covered in HPLC vs. mass spectrometry, and the area-percent calculation is explained in understanding HPLC purity.
Impurities an analyst looks for
- Deletion and truncated sequences from incomplete coupling steps, visible as peaks at lower mass and usually eluting earlier.
- Des-acyl peptide (the backbone without the fatty diacid), which is far less hydrophobic and elutes much earlier than the main peak. Its mass is lower by the mass of the linker-lipid unit.
- Over-acylated or mis-acylated forms, where a second site carries lipid or the lipid sits on the wrong residue. A second acylation is a large, unmistakable mass shift; a positional isomer has the same mass and may be separable only by retention time.
- Oxidized species (+16 Da) at the tryptophan, and deamidated species (about +1 Da) at glutamine or asparagine positions. The +1 Da shift is easy to miss without adequate mass resolution.
- Aggregates, which a lipidated peptide is more prone to forming than an unmodified one, and which may not be visible in a standard reversed-phase run.
Reading the analytical package
Purity and identity numbers are only meaningful when tied to the specific batch a researcher is holding. A Certificate of Analysis should list the lot number, the purity result and the method used to obtain it, the confirmed molecular mass, and the date of testing, not a generic specification sheet reused across every batch a supplier has ever sold. How to read a Certificate of Analysis walks through each of those fields and what to check before trusting a COA. The product page links a published lot certificate, and further batch records are searchable on the CoA page.
| Report item | Acceptable | Warning sign |
|---|---|---|
| Lot number | Matches the vial label | Missing, or identical across different products |
| HPLC purity | Stated with method, column and wavelength; chromatogram attached | Typed percentage only |
| Observed mass | Close to about 4,813 Da, shown beside the expected value | Absent, or "conforms" with no number |
| Minor peaks | Listed individually | Merged into the baseline or ignored |
| Test date | Near the production date | Old document reused for new lots |
| Laboratory | Named or on file | Not identified |
Independent verification
Because an in-house COA is still a claim made by the seller about its own product, independent laboratory testing adds a layer of verification that doesn’t rely on taking the supplier’s word for it. Third-party testing explained covers how that process works and what it can and cannot confirm. V8 Peptides lists tirzepatide at ≥98% HPLC purity, and the product page shows the identity-tested status and a link to the lot’s COA.
Beyond purity and mass
Some research programs additionally screen for residual solvents left over from synthesis and purification, and for bacterial endotoxin, particularly when material will be used in cell-culture work where contamination can confound an assay’s readout. These checks aren’t always included on a standard COA and are worth asking a supplier about directly if a planned experiment depends on them. Residual trifluoroacetate, a typical counter-ion from reversed-phase purification, can also affect cell assays at high concentration, so some labs request an exchange to acetate.
Net peptide content and concentration
Labeled vial mass is the weight of the lyophilized solid, which includes counter-ions and residual water. Area-percent purity does not capture that. For a 30 mg vial, the nominal concentration after adding diluent is simply mass divided by volume: 30 mg in 3 mL gives 10 mg/mL, and 30 mg in 6 mL gives 5 mg/mL. If a lab needs the true peptide concentration, it multiplies by the net peptide content stated for the lot. The reconstitution calculator does the arithmetic, and handling specifics, including why a lipidated peptide may need gentle mixing, are in tirzepatide reconstitution and handling.
What stability testing adds
A certificate describes the lot on the day it was tested. Lipidated peptides can behave differently in solution from unmodified ones, because the fatty chain promotes self-association and adsorption to surfaces. If an experiment runs over days, re-checking a retained aliquot by HPLC is the only way to know whether the peak you started with is the peak you finish with. Storage conditions and expected stability behavior are summarized in tirzepatide storage and stability; the product page specifies refrigeration at 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light.
How tirzepatide testing compares with related peptides
The same two-part logic applies to the other incretin-class materials, but the details differ. Retatrutide adds a third receptor activity and has its own impurity profile, covered in retatrutide purity testing; semaglutide is a different lipidated backbone, covered in semaglutide purity testing. For sourcing criteria that apply across all of them, see the semaglutide and tirzepatide buyer’s guide and the tirzepatide sourcing guide. Pricing context is in what drives tirzepatide cost, where analytical verification is one of the named cost factors.
Research Use Only. For laboratory research use only; not for human consumption. Not for veterinary or diagnostic purposes. This article is research education, not usage guidance.
Frequently asked questions
What does HPLC tell me about tirzepatide?
It reports the share of detected peak area that belongs to the main peak, which is the purity figure. It does not by itself prove the main peak is tirzepatide.
What does mass spectrometry add?
It measures the molecular mass of the main component and compares it with the expected value for C225H348N48O68, about 4,813 Da. An acylation error would appear as a mass shift.
Why is the lipid side chain important for quality control?
Missing, doubled or misplaced acylation produces impurities with very different hydrophobicity and mass. Those are the failure modes specific to this molecule.
Is a purity of ≥98% sufficient on its own?
No. It should be backed by a chromatogram, an observed mass, a lot number, a method and a date. Without those, the number cannot be checked.
Can a certificate confirm sterility or endotoxin levels?
Only if those tests are listed on it. Purity and identity do not imply sterility or endotoxin results.
Where do I find the certificate for my lot?
The product page links a published lot COA, and further batch records are on the CoA page. Match the lot number to your vial.
How do I calculate the concentration of a reconstituted stock?
Divide the vial mass by the diluent volume. For example, 30 mg in 3 mL is 10 mg/mL. Multiply by net peptide content for the true peptide concentration.
Does analytical purity say anything about activity?
No. Chemical testing establishes what the material is. Receptor activity in a given assay has to be demonstrated experimentally with suitable controls.
References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.
- V8 Peptides. Tirzepatide research peptide product page.
- V8 Peptides. Tirzepatide research overview.
- V8 Peptides. How to read a certificate of analysis.